SEC 13F Intelligence

Managers / Q3 2023 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$192M
Q3 2023
Positions
72
Filings on Record
25
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Altium Capital Management LLC reported $192M in U.S.-listed holdings across 72 positions for Q3 2023.

Its largest position, Cymabay Therapeutics, represents 6.2% of the portfolio.

Compared with Q2 2023, the fund opened 23 new positions and exited 19.

Portfolio Metrics

Turnover
+25.9%
vs prior filed quarter
Top-10 Concentration
+49.7%
share of reported value
Largest Position
+6.2%
Cymabay Therapeutics
New / Exited
23 / 19
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $266MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 74.0%Other: 21.1%ADR: 4.3%Equity WRT: 0.6%
  • Common Stock · 74.0% · $142M
  • Other · 21.1% · $40M
  • ADR · 4.3% · $8M
  • Equity WRT · 0.6% · $1M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
IMMUNOVANT INCNEW+300.0K300.0K+$12M$12M
ALIMERA SCIENCES INCNEW+2.93M2.93M+$9M$9M
GPCRSTRUCTURE THERAPEUTICS INCNEW+155.0K155.0K+$8M$8M
BHVNBIOHAVEN LTDNEW+287.0K287.0K+$7M$7M
KARUNA THERAPEUTICS INCNEW+34.0K34.0K+$6M$6M
SGMTSAGIMET BIOSCIENCES INCNEW+483.2K483.2K+$4M$4M
APELLIS PHARMACEUTICALS INCNEW+100.0K100.0K+$4M$4M
ACRSACLARIS THERAPEUTICS INCNEW+403.0K403.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

65 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1CYMABAY THERAPEUTICS INCCOM6.22%$12M800.0K
2IMMUNOGEN INCCOM6.00%$12M725.0K
3ASTRIA THERAPEUTICS INCCOM5.24%$10M1.35M
4XTNTXTANT MED HLDGS INChistory →COM NEW5.13%$10M8.93M
5AMLXAMYLYX PHARMACEUTICALS INChistory →COM5.11%$10M534.7K
6ADMAADMA BIOLOGICS INChistory →COM5.08%$10M2.72M
7ALIMERA SCIENCES INCCOM NEW4.74%$9M2.93M
8GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS4.08%$8M155.0K
9CRNXCRINETICS PHARMACEUTICALS INhistory →COM4.06%$8M262.0K
10XENEXENON PHARMACEUTICALS INChistory →COM4.06%$8M228.0K
11BHVNBIOHAVEN LTDhistory →COM3.89%$7M287.0K
12AXSMAXSOME THERAPEUTICS INChistory →COM3.35%$6M92.0K
13KARUNA THERAPEUTICS INCCOM3.00%$6M34.0K
14MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD2.62%$5M88.0K
15VERAVERA THERAPEUTICS INChistory →CL A2.39%$5M333.7K
16SGMTSAGIMET BIOSCIENCES INChistory →COM SER A2.22%$4M483.2K
17OLMAOLEMA PHARMACEUTICALS INChistory →COM2.16%$4M335.0K
18HRMYHARMONY BIOSCIENCES HLDGS INhistory →COM2.00%$4M117.0K
19SRPTSAREPTA THERAPEUTICS INChistory →COM1.85%$4M29.3K
20DYNDYNE THERAPEUTICS INChistory →COM1.47%$3M315.0K
21ACRSACLARIS THERAPEUTICS INChistory →COM1.44%$3M403.0K
22ABOSACUMEN PHARMACEUTICALS INChistory →COM1.41%$3M650.0K
23REPLREPLIMUNE GROUP INChistory →COM1.38%$3M155.0K
24ORICORIC PHARMACEUTICALS INChistory →COM1.32%$3M418.7K
25COGTCOGENT BIOSCIENCES INChistory →COM1.19%$2M235.0K
26PHATPHATHOM PHARMACEUTICALS INChistory →COM1.19%$2M220.0K
27JASPER THERAPEUTICS INCCOM1.05%$2M2.87M
28INTRA-CELLULAR THERAPIES INCCOM0.76%$1M28.0K
29SOLENO THERAPEUTICS INCCOM0.72%$1M47.1K
30MERSANA THERAPEUTICS INCCOM0.70%$1M1.06M
31DMACDIAMEDICA THERAPEUTICS INCCOM NEW0.67%$1M496.0K
32PRAXIS PRECISION MEDICINES ICOM0.58%$1M650.0K
33MARINUS PHARMACEUTICALS INCCOM NEW0.52%$1M125.0K
34KARYOPHARM THERAPEUTICS INCCOM0.52%$991,600740.0K
35FAT BRANDS INC*W EXP 07/16/2020.51%$974,000200.0K
36GRI BIO INCCOM0.42%$808,337521.5K
37SADOT GROUP INCCOM0.32%$604,819865.3K
38DDIDOUBLEDOWN INTERACTIVE CO LTADS0.27%$516,22860.9K
39SNOW LAKE RES LTDCOM0.15%$289,587219.4K
40WEARABLE DEVICES LTD*W EXP 09/14/2020.09%$168,4741.41M
41DIRECT DIGITAL HOLDINGS INC*W EXP 02/15/2020.06%$108,018180.0K
42NOCTURNE ACQUISITION CORPRIGHT 12/26/20250.04%$78,250500.0K
43NXGLWNEXGEL INC*W EXP 12/01/2020.04%$76,500225.0K
44CINGWCINGULATE INC*W EXP 12/10/2020.02%$44,550270.0K
45ONFOWONFOLIO HOLDINGS INC*W EXP 01/02/2020.01%$26,680200.0K
46PEPPERLIME HEALTH ACQUSTN CO*W EXP 10/01/2020.01%$26,093367.5K
47JEFFS BRANDS LTD*W EXP 08/26/2020.01%$21,394480.8K
48NLS PHARMACEUTICS LTD*W EXP 02/02/2020.01%$21,040200.0K
49HARBOR CUSTOM DEVELOPMENT IN*W EXP 10/07/202 · *W EXP 05/09/2020.01%$10,9351.25M
50PROSOMNUS INC*W EXP 04/20/2020.01%$10,500150.0K
51BTMWQBITCOIN DEPOT INC*W EXP 06/30/2020.00%$9,49550.0K
52BNCWWCEA INDUSTRIES INC*W EXP 02/11/2020.00%$9,200250.0K
53TG VENTURE ACQUISITION CORP*W EXP 08/15/2020.00%$6,400200.0K
54CONDUIT PHARMACEUTICALS INC*W EXP 09/22/2020.00%$4,500100.0K
55CHAVANT CAPITAL ACQUISITN CO*W EXP 99/99/9990.00%$4,380150.0K
56COLISEUM ACQUISITION CORP*W EXP 08/22/2020.00%$3,61228.3K
57SRZNWSURROZEN INC*W EXP 08/01/2030.00%$3,38082.2K
58DIGITAL HEALTH ACQUISITION C*W EXP 11/02/2020.00%$3,315150.0K
59CYCUWWESTERN ACQSTN VENTURES CORP*W EXP 09/01/2020.00%$3,210100.0K
60NEXALIN TECHNOLOGY INC*W EXP 09/15/2020.00%$2,625105.0K
61SELINA HOSPITALITY PLC*W EXP 10/27/2020.00%$1,420101.4K
62OPY ACQUISITION CORP I*W EXP 09/22/2020.00%$1,38550.0K
63TCBWFTC BIOPHARM HOLDINGS PLC*W EXP 02/08/2020.00%$39318.8K
64BRSWFBRUUSH ORAL CARE INC*W EXP 08/03/2020.00%$34214.4K
65RELATIVITY ACQUISITION CORP*W EXP 12/15/2020.00%$0100.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$266M98Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.